美康生物(300439.SZ)擬定增募資不超6億元 用於體外診斷產品研發及產業化項目等
格隆匯 6 月 29日丨美康生物(300439.SZ)披露2020年向特定對象發行股票預案,公司此次向特定對象發行股票募集資金總額不超過6億元(含6億元),在扣除發行費用後擬投入下列項目:1.7億元用於體外診斷產品研發及產業化項目;2.6億元用於信息系統升級項目;1.7億元用於償還銀行借款。
此次向特定對象發行股票的數量按照募集資金總額除以發行價格確定,同時此次向特定對象發行股票的數量不超過此次發行前公司總股本的30%,即不超過約1.04億股(含約1.04億股),並以中國證監會關於此次發行的批覆文件為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.